Amylyx Pharmaceuticals (AMLX) Superinvestor holders
11 of the superinvestors we track hold Amylyx Pharmaceuticals (AMLX) in their latest 13F filings, $31M in total.
Summary
The largest holder is Two Sigma (Two Sigma Investments), with $11M, 0.0% of the portfolio.
In their latest quarter: 6 opened a new position, 3 added, 2 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Two Sigma Two Sigma Investments |
Added | 593,435 | $11M | 0.0% | Q2 2026 |
| Wilmot Harkey Nantahala Capital Management |
Trimmed | 486,684 | $9M | 0.5% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
New position | 305,441 | $5M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 174,285 | $3M | 0.0% | Q2 2026 |
| Jennison Associates | New position | 35,841 | $643,705 | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Added | 35,410 | $635,964 | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 20,819 | $373,909 | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
New position | 7,701 | $224,000 | 0.0% | Q3 2026 |
| Ken Tropin Graham Capital Management |
New position | 12,364 | $222,057 | 0.0% | Q2 2026 |
| Alec Litowitz Magnetar Capital |
New position | 11,722 | $210,527 | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
New position | 11,611 | $208,534 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 10 |
| Q1 2026 | 6 |
| Q4 2025 | 9 |
| Q3 2025 | 10 |
| Q2 2025 | 8 |
| Q1 2025 | 10 |
| Q4 2024 | 9 |
| Q3 2024 | 11 |
Questions about Amylyx Pharmaceuticals
Which superinvestors own Amylyx Pharmaceuticals?
11 of the superinvestors we track hold Amylyx Pharmaceuticals (AMLX) in their latest 13F filings, $31M in total. Two Sigma, Wilmot Harkey, Ensign Peak, David Shaw, Jennison Associates, Paul Tudor Jones.
Who is the largest superinvestor holder of AMLX?
The largest holder is Two Sigma (Two Sigma Investments), with $11M, 0.0% of the portfolio.
From Amylyx Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.